Significant differences in cellular and plasma biomarkers between newly diagnosed BOS and no-cGVHD patients in univariate analysis
| . | All BOS . | NIH-BOS . | Other BOS . | No cGVHD . | cGVHD skin . | P NIH-BOS vs other BOS . | P BOS vs no cGVHD . | P BOS vs skin GVHD . |
|---|---|---|---|---|---|---|---|---|
| Number of patients | 46 | 40 | 6 | 41 | 49 | |||
| BAFF, ng/mL | 7.3 | 7.5 | 7.0 | 3.5 | 4.5 | .63 | .02 | .03 |
| CD19+ B cells × 106/L | 146 | 141 | 178 | 317 | 231 | .5 | <.0001 | .05 |
| CD19+ B cells, % of lymphocytes | 10.2 | 10.1 | 16.3 | 19.7 | 11.2 | .14 | <.0001 | .67 |
| Ratio ng BAFF/CD19+ × 103 B cells | 0.18 | 0.19 | 0.15 | 0.02 | 0.05 | .8 | .007 | .003 |
| CD19+CD21low B cells, % of CD19+ B cells | 25.5 | 26.4 | 16.5 | 6.6 | 7.2 | .18 | <.0001 | <.0001 |
| IgG, mg/dL | 533 | 522 | 605 | 1172 | 754 | .5 | <.0001 | .03 |
| CD4+ T-cells, % of lymphocytes | 23.6 | 23.2 | 26.7 | 17.5 | 24.4 | .41 | .004 | .7 |
| . | All BOS . | NIH-BOS . | Other BOS . | No cGVHD . | cGVHD skin . | P NIH-BOS vs other BOS . | P BOS vs no cGVHD . | P BOS vs skin GVHD . |
|---|---|---|---|---|---|---|---|---|
| Number of patients | 46 | 40 | 6 | 41 | 49 | |||
| BAFF, ng/mL | 7.3 | 7.5 | 7.0 | 3.5 | 4.5 | .63 | .02 | .03 |
| CD19+ B cells × 106/L | 146 | 141 | 178 | 317 | 231 | .5 | <.0001 | .05 |
| CD19+ B cells, % of lymphocytes | 10.2 | 10.1 | 16.3 | 19.7 | 11.2 | .14 | <.0001 | .67 |
| Ratio ng BAFF/CD19+ × 103 B cells | 0.18 | 0.19 | 0.15 | 0.02 | 0.05 | .8 | .007 | .003 |
| CD19+CD21low B cells, % of CD19+ B cells | 25.5 | 26.4 | 16.5 | 6.6 | 7.2 | .18 | <.0001 | <.0001 |
| IgG, mg/dL | 533 | 522 | 605 | 1172 | 754 | .5 | <.0001 | .03 |
| CD4+ T-cells, % of lymphocytes | 23.6 | 23.2 | 26.7 | 17.5 | 24.4 | .41 | .004 | .7 |
Patients with cGVHD had erythematous lesions alone (n = 37), erythematous lesions and moveable sclerosis (n = 4), moveable sclerosis alone (n = 2), or superficial and deep sclerotic features (n = 6). NIH-BOS, BOS defined according to the modified NIH criteria7,15 ; other BOS, patients not fulfilling all criteria of the NIH definition but having BOS according to pulmonary specialist assessment.